439 related articles for article (PubMed ID: 26857707)
1. Expanding roles of the hypoxia-response network in chronic kidney disease.
Tanaka T
Clin Exp Nephrol; 2016 Dec; 20(6):835-844. PubMed ID: 26857707
[TBL] [Abstract][Full Text] [Related]
2. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Nangaku M
Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
[TBL] [Abstract][Full Text] [Related]
3. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.
Liu J; Wei Q; Guo C; Dong G; Liu Y; Tang C; Dong Z
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468297
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
7. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.
Sugahara M; Tanaka T; Nangaku M
Kidney360; 2020 Sep; 1(9):1021-1031. PubMed ID: 35369554
[TBL] [Abstract][Full Text] [Related]
9. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic link between renal ischemia and fibrosis.
Tanaka T
Med Mol Morphol; 2017 Mar; 50(1):1-8. PubMed ID: 27438710
[TBL] [Abstract][Full Text] [Related]
11. [Multiple consequences of HIF activation in CKD].
Tanaka T
Nihon Yakurigaku Zasshi; 2020; 155(1):30-34. PubMed ID: 31902844
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
[TBL] [Abstract][Full Text] [Related]
13. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease.
Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):43-50. PubMed ID: 19779337
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-Inducible Factors and Diabetic Kidney Disease-How Deep Can We Go?
Stanigut AM; Pana C; Enciu M; Deacu M; Cimpineanu B; Tuta LA
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142323
[TBL] [Abstract][Full Text] [Related]
15. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
Tanaka T; Eckardt KU
Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
[TBL] [Abstract][Full Text] [Related]
16. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure.
Nangaku M
J Am Soc Nephrol; 2006 Jan; 17(1):17-25. PubMed ID: 16291837
[TBL] [Abstract][Full Text] [Related]
17. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
19. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
20. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
